The bill aims to enhance the management and treatment of Sickle Cell Disease (SCD) within the MassHealth program by providing a comprehensive report on the prevalence, treatments, and healthcare services available to enrollees diagnosed with SCD. It highlights that from July 1, 2022, to June 30, 2024, there were 1,831 enrollees with SCD, primarily aged 21 to 45 years. The report details medications covered by MassHealth, including hydroxyurea and other disease-modifying agents, while noting that Oxbryta (voxelotor) will no longer be covered as of January 2025 due to its market withdrawal. The bill also emphasizes the importance of infection prevention measures and addresses the adequacy of healthcare services, including the transition from pediatric to adult care and emergency service training for SCD-related crises.

Furthermore, the bill introduces new legal language to incorporate updated ICD-10 and GSN codes for various SCD treatments and medications, ensuring healthcare providers have accurate billing and treatment protocols. It emphasizes the need for improved access to treatment, culturally sensitive care, and greater support in educational settings for individuals with SCD. The bill also outlines the responsibilities of Accountable Care Organizations (ACOs) and Community Partner programs in providing comprehensive, family-centered care for children with complex medical needs, particularly those in foster care. Overall, the bill aims to enhance healthcare delivery, access to medications, and the overall quality of care for individuals living with SCD in Massachusetts.